In animal studies to validate the in vitro effect of CPSF6, CPSF6 depletion suppressed the volume of Hep3B cells and liver weight in BALB/c mice in orthotopic and xenograft tumor models, attenuated the expression of c-Myc, PCNA, VEGF, PD-L1, HK2, PKM2, and LDH, and activated the expression of caspase 3 by immunohistochemistry, strongly demonstrating that CPSF6 can be a therapeutic target in liver cancer therapy. The gene discussed is PKM; the disease is neoplasm.